Bevacizumab in therapy-refractory epistaxis. Case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia

被引：2
作者：
Rohrmeier, C. [1 ]
Kuehnel, T. S. [1 ]
机构：
[1] Univ Klinikum Regensburg, Klin Hals Nasen Ohren Heilkunde Kopf & Halschirur, D-93053 Regensburg, Germany
来源：
HNO | 2012年 / 60卷 / 11期
关键词：
Hereditary hemorrhagic telangiectasia; Osler disease; Bevacizumab; Epistaxis; Case report;
D O I：
10.1007/s00106-011-2458-x
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.
引用
收藏
页码：1003 / 1006
页数：4
相关论文
共 48 条
[41]   Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report [J].
Meng, Xiangying ;
Zhao, Rugang ;
Wu, Shikai ;
Shen, Ge ;
Ding, Lijuan ;
Sun, Bing ;
Wang, Junliang .
CANCER BIOLOGY & THERAPY, 2017, 18 (01) :63-66
[42]   Low-dose bevacizumab as an effective pre-treatment for peri-tumoral brain edema prior to CyberKnife radiosurgery: A case report [J].
Meng Xiangying ;
Zhao Rugang ;
Ding Lijuan ;
Zhao Yaowei ;
Sun Bing ;
Wang Junliang ;
Li Dan ;
Wu Shikai .
CANCER BIOLOGY & THERAPY, 2018, 19 (06) :461-464
[43]   Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report [J].
Peng, Shang-Hsuan ;
Chen, Bang-Bin ;
Kuo, Ting-Chun ;
Lee, Jen-Chieh ;
Yang, Shih-Hung .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[44]   Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: A case report [J].
Linsenmann T. ;
Monoranu C.M. ;
Vince G.H. ;
Westermaier T. ;
Hagemann C. ;
Kessler A.F. ;
Ernestus R.-I. ;
Löhr M. .
BMC Research Notes, 7 (1)
[45]   Case Report: High efficacy of low-dose flecainide as an add-on therapy to a beta-blocker for treating a high burden of idiopathic ventricular arrhythmias in a juvenile athlete [J].
Christou, Georgios A. ;
Letsas, Konstantinos P. ;
Konstandi, Maria ;
Christou, Maria A. ;
Christou, Konstantinos A. ;
Kyriakopoulos, Christos ;
Vidalakis, Eleftherios ;
Tigas, Stelios ;
Christodoulou, Dimitrios K. ;
Kiortsis, Dimitrios N. .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2025, 12
[46]   Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report(vol 14, 1372295, 2024 [J].
Castelli, Barbara ;
Fonte, Carla ;
Guidi, Milena ;
Tellini, Marco ;
Di Nicola, Marco ;
Iacono, Alessandro ;
Buccoliero, Anna Maria ;
Greto, Daniela ;
Genitori, Lorenzo ;
Sardi, Iacopo .
FRONTIERS IN ONCOLOGY, 2024, 14
[47]   Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report [J].
Al-Mashdali, Abdulrahman F. ;
Kashgary, Waail R. ;
Yassin, Mohamed A. .
MEDICINE, 2021, 100 (44)
[48]   Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report [J].
Komiyama, Satoshi ;
Numata, Kazushi ;
Ogushi, Katsuaki ;
Chuma, Makoto ;
Tanaka, Reiko ;
Chiba, Sawako ;
Otani, Masako ;
Inayama, Yoshiaki ;
Nakano, Masayuki ;
Maeda, Shin .
DIAGNOSTICS, 2021, 11 (08)
12345